Allena Pharmaceuticals (NASDAQ:ALNA) posted its earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01, MarketWatch Earnings reports.
Shares of NASDAQ:ALNA traded down $0.08 during trading on Wednesday, reaching $1.08. The company had a trading volume of 25,046 shares, compared to its average volume of 1,817,283. The company has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.46. The stock has a market capitalization of $62.22 million, a P/E ratio of -0.92 and a beta of 2.39. Allena Pharmaceuticals has a 12 month low of $1.02 and a 12 month high of $3.39. The company has a current ratio of 7.99, a quick ratio of 7.99 and a debt-to-equity ratio of 0.54.
Separately, Zacks Investment Research lowered shares of Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Allena Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $9.00.
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Article: How does a dividend reinvestment plan work?
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.